Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a clinical-stage
biopharmaceutical company pursuing novel therapeutics for
nonalcoholic steatohepatitis (NASH), today announced that it has
commenced an underwritten public offering of $500 million in shares
of its common stock and, to certain investors, pre-funded warrants
to purchase common stock. The purchase price of each pre-funded
warrant will equal the price per share at which shares of common
stock are being sold to the public in this offering, minus $0.0001,
which will be the per share exercise price of each pre-funded
warrant. Madrigal also intends to grant the underwriters a 30-day
option to purchase up to an additional fifteen percent (15%) of the
shares of common stock offered in the public offering at the public
offering price, less underwriting discounts and commissions. All of
the shares in the proposed offering are to be sold by Madrigal.
Madrigal intends to use the net proceeds from this offering for
its clinical and commercial activities in preparation for a
potential launch of resmetirom in the U.S. and for general
corporate purposes, including, without limitation, research and
development expenditures, clinical trial expenditures, manufacture
and supply of drug substance and drug products, potential
acquisitions or licensing of new technologies, capital expenditures
and working capital.
Goldman Sachs & Co. LLC, Jefferies, TD Cowen, Evercore ISI
and Piper Sandler are acting as joint bookrunning managers of the
proposed offering. The offering is subject to market and other
conditions, and there can be no assurance as to whether or when the
offering may be completed, or as to the actual size or terms of the
offering.
The shares are being offered by Madrigal pursuant to an
effective shelf registration statement on Form S-3 that was
previously filed with the Securities and Exchange Commission (SEC)
on June 1, 2021. A preliminary prospectus supplement and the
accompanying prospectus relating to and describing the terms of the
offering is expected to be filed with the SEC and, when filed, will
be available on the SEC’s website at www.sec.gov. Alternatively,
copies of the preliminary prospectus supplement and the
accompanying prospectus relating to these securities may also be
obtained by contacting the following: Goldman Sachs & Co. LLC,
Attn: Prospectus Department, 200 West Street, New York, New York
10282, telephone: 1-866-471-2526, email:
prospectus-ny@ny.email.gs.com; Jefferies LLC, Attn: Equity
Syndicate Prospectus Department, 520 Madison Avenue, New York, NY
10022, by telephone at (877) 821-7388, or by email at
Prospectus_Department@jefferies.com; Cowen and Company, LLC, 599
Lexington Avenue, New York, NY 10022, by telephone at (833)
297-2926 or by email at Prospectus_ECM@cowen.com; Evercore Group
L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street,
35th Floor, New York, New York 10055, by telephone at (888)
474-0200, or by email at ecm.prospectus@evercore.com; or Piper
Sandler & Co., 800 Nicollet Mall, J12S03, Minneapolis, MN
55402, Attention: Prospectus Department, by telephone at (800)
747-3924 or by email at prospectus@psc.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of,
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of such state or
jurisdiction.
About Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a
clinical-stage biopharmaceutical company pursuing novel
therapeutics for nonalcoholic steatohepatitis (NASH), a liver
disease with high unmet medical need. Madrigal’s lead candidate,
resmetirom, is a once daily, oral, thyroid hormone receptor (THR)-ß
selective agonist designed to target key underlying causes of NASH
in the liver.
Forward-Looking Statements
Forward-looking statements reflect management’s current
knowledge, assumptions, judgment and expectations regarding
forward-looking statements, future performance or events; include
all statements that are not historical facts; and can be identified
by terms such as “be,” “can,” “designed,” “expectation,” “may,”
“plans,” “seeks,” “will,” “will be,” “would” or similar expressions
and the negatives of those terms.
Statements in this release concerning Madrigal’s future
expectations, plans and prospects, including, without limitation,
statements about Madrigal’s proposed public offering and use of
proceeds, constitute forward-looking statements for the purposes of
the safe harbor provisions under the Private Securities Litigation
Reform Act of 1995. Actual results and future plans may differ
materially from those indicated by these forward-looking statements
as a result of various important factors, including, without
limitation, risks associated with market conditions and the timing
and success of the proposed offering and the anticipated use of
proceeds from the proposed offering, as well as those risks more
fully discussed in the “Risk Factors” filed in Part I, Item 1A of
Madrigal’s Annual Report on Form 10-K for the year ended December
31, 2022, as amended by its Form 10-K/A filed with the SEC on March
3, 2023 and Part II, Item 1A of Madrigal’s Quarterly Report on Form
10-Q for the quarter ended June 30, 2023, and in other filings that
Madrigal makes with the SEC, including those included or
incorporated by reference in the preliminary prospectus supplement
and accompanying prospectus supplement related to the proposed
public offering expected to be filed with the SEC. There can be no
assurance that Madrigal will be able to complete the proposed
public offering on the anticipated terms, or at all. You should not
place undue reliance on these forward-looking statements. In
addition, any forward-looking statements represent Madrigal’s views
only as of today and should not be relied upon as representing its
views as of any subsequent date. Madrigal explicitly disclaims any
obligation, except to the extent required by law, to update any
forward-looking statements.
Investor ContactAlex Howarth, Madrigal
Pharmaceuticals, Inc., IR@madrigalpharma.com
Media ContactChristopher Frates, Madrigal
Pharmaceuticals, Inc., media@madrigalpharma.com
Madrigal Pharmaceuticals (NASDAQ:MDGL)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Madrigal Pharmaceuticals (NASDAQ:MDGL)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024